Drug Database
GE

gemigliptin + dapagliflozin (LR 19051 / LR19051)

✓ Approved

LG Chem Ltd. · DPP4 · 小分子

什么是 gemigliptin + dapagliflozin?

gemigliptin + dapagliflozin 是一种小分子,由LG Chem Ltd.研发。该药已获批,用于治疗相关适应症,给药途径:Unknown。

药物档案

商品名LR 19051, LR19051
公司LG Chem Ltd.
药物类别小分子
分子靶点DPP4, SLC5A2
给药途径Unknown
状态Approved

作用机制

分子靶点

gemigliptin + dapagliflozin 作用于 2 个分子靶点:

DPP4dipeptidyl peptidase 4 (CD26, DPPIV)
SLC5A2solute carrier family 5 member 2 (SGLT2)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

gemigliptin + dapagliflozin 针对 1 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Metabolism and nutrition disordersType 2 diabetes mellitus✓ Approved

相关研究文献

PubMedJACC. Basic to translational science2026-11-18

Effect of Prereperfusion Dapagliflozin Loading on Infarct Size, Mitochondrial Function, and Ventricular Remodeling in ST-Segment Elevation Myocardial Infarction: A Randomized Controlled Trial.

Suwannasom Pannipa P, Apaijai Nattayaporn N, Noparatkailas Nabhat N, Leemasawat Krit K et al.

Sodium-glucose cotransporter-2 inhibitors demonstrate cardioprotective effects in preclinical ischemia-reperfusion models, potentially mediated by mitochondrial modulation, but their benefit in acute ST-segment elevation myocardial infarction remains uncertain. In this randomized, double-blind, placebo-controlled trial, 60 patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention were assigned to dapagliflozin (20 mg prereperfusion followed by 10 mg daily) or placebo for 12 weeks. The primary endpoint was enzymatic infarct size assessed by the 72-hour area under the curve of high-sensitivity cardiac troponin I. Dapagliflozin did not reduce infarct size compared with placebo (adjusted difference: -0.89 × 106 arbitrary unit; P = 0.47). Although mitochondrial respiratory capacity increases transiently at 2 weeks, this effect was not sustained. Left ventricular function improved similarly in both groups, and cardiac magnetic resonance-derived infarct size did not differ significantly. Prereperfusion dapagliflozin was not associated with reduced infarct size despite transient mitochondrial modulation. The neutral findings should be interpreted in the context of the brief drug-to-wire interval and the limited statistical power of this pilot trial.

PMID 43050799
阅读全文 →
PubMedCanadian journal of kidney health and disease2026-11-18

Systematic Review of the Cost-Utility of Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors for Chronic Kidney Disease Management.

Watema-Lord Ronald R, Xie Feng F, Sanyal Chiranjeev C

Chronic kidney disease (CKD) represents a progressive and severe medical condition that imposes a substantial economic burden. This systematic review aimed to summarize the available evidence regarding the costs and cost-utility of SGLT2 inhibitors in managing CKD. A systematic literature search was conducted from inception to November 07, 2025, using MEDLINE, EMBASE, and Scopus databases. Titles and abstracts were screened, followed by an eligibility assessment of full texts. The quality of the studies was evaluated using the Quality of Health Economic Studies (QHES) and Consolidated Health Economic Evaluation Reporting Standards (CHEERS) checklists. Cost-utility results were synthesized narratively. Thirteen cost-utility studies met the inclusion criteria, evaluating Dapagliflozin, Empagliflozin, and Canagliflozin. The addition of Empagliflozin or Dapagliflozin to standard care (SoC) was cost-effective compared with SoC alone in patients with chronic kidney disease (CKD), regardless of type 2 diabetes (T2D) status. Among CKD patients with T2D, SGLT2 inhibitors combined with SoC were cost-saving in high-income countries from a health system perspective; however, Dapagliflozin was not cost-effective when compared to Canagliflozin. No study fulfilled all criteria of the QHES and CHEERS checklists. This systematic review has several limitations, including restriction to English-language studies, potential subjectivity in methodological and reporting quality assessments, and possible publication bias. In addition, heterogeneity in study settings, interventions, and service utilization limits direct comparisons across studies, although the findings provide valuable insights into the cost-utility of SGLT2 inhibitors for CKD management.

PMID 43048412
阅读全文 →
PubMedPaediatric drugs2026-11-18

Adverse Effects of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors in Pediatric Heart Failure: A Systematic Review and Meta-Analysis of Proportions.

Cakan Boran B, Ardali Aylin A, Odemis Ender E

Sodium-glucose cotransporter-2 (SGLT2) inhibitors have become a foundational therapy for adult heart failure across the entire spectrum of ejection fraction, but their safety profile in children with heart failure has not been quantitatively synthesized. We conducted a systematic review and meta-analysis of proportions to summarize the incidence of adverse events associated with SGLT2 inhibitors in pediatric heart failure. In this systematic review and meta-analysis of proportions (PROSPERO CRD420261355711; PRISMA 2020), five databases were searched through June 2026 for studies of any design reporting adverse events among pediatric patients receiving an SGLT2 inhibitor for heart failure. Random-effects incidence estimates were pooled using logit-transformed proportions with restricted maximum-likelihood estimation and modified Hartung-Knapp-Sidik-Jonkman confidence intervals; risk of bias and GRADE certainty were assessed. Ten studies (573 unique children; 2023-2026) were included; eight studies (572 patients; maximum pooled denominator 474) were meta-analyzed, and one case report was summarized narratively. Dapagliflozin accounted for 94.1% of exposures. Study-level dapagliflozin doses ranged from 0.11 to 0.23 mg/kg/day, while the single cohort reporting empagliflozin used a median dose of 0.13 mg/kg/day. No regimen was derived from pediatric heart-failure pharmacokinetic data, and in the only cohort reporting a comparison, infants received a higher weight-normalized dose than older children (0.18 versus 0.16 mg/kg/day). Pooled incidences were: any adverse event 21.2% (95% CI 10.7-37.8%), acute kidney injury 10.7% (3.5-28.1%), urinary tract infection 7.8% (4.8-12.4%), treatment discontinuation 7.0% (4.5-10.6%), all-cause mortality 5.6% (2.4-12.5%), hypoglycemia 2.9% (0.9-9.3%), genital mycotic infection 2.7% (0.9-8.2%), and diabetic ketoacidosis 1.3% (0.4-3.9%). No deaths were attributed to therapy, and no cases of euglycemic ketoacidosis or Fournier gangrene occurred. Directional efficacy signals were consistently favorable, with left ventricular ejection fraction improving in five of six cohorts and natriuretic peptide levels declining across all seven in which they were assessed. SGLT2 inhibitors had a tolerable safety profile in pediatric heart failure, mirroring the adult experience. Adequately powered randomized trials with standardized adverse-event grading are needed. PROSPERO identifier no. CRD420261355711.

PMID 43050033
阅读全文 →
PubMedCellular and molecular life sciences : CMLS2026-11-18

Tissue-specific metabolomics in experimental HFpEF reveals hepatic remodelling modulated by SGLT2 inhibition.

Kiyar Muhammed M, Magaye Ruth R, Bailey Shanae S, Wang XiaoSuo X et al.

Recent favourable clinical trials of sodium-glucose transporter 2 (SGLT2) inhibitors and glucagon-like-peptide-1 (GLP-1) agonists have substantially changed the management landscape for heart failure with preserved ejection fraction (HFpEF) patients. However, the organ-level metabolic mechanisms underpinning these benefits remain incompletely understood and it is unclear how these therapies reshape inter-organ metabolic crosstalk in HFpEF. In many patients, the HFpEF phenotype appears to result from an intersection between abnormal cardiovascular physiology together with metabolic and inflammatory changes. Experimental HFpEF was induced in 18-month-old female C57BL/6J mice with a high-fat diet for 12 weeks, an angiotensin II infusion beginning at week 6, with age-matched controls, to establish a cardiometabolic phenotype. Treatment with the SGLT2 inhibitor Dapagliflozin (Dapa) was administered for 6 weeks, concurrently with AngII administration. In addition to comprehensive cardiovascular and inflammatory phenotyping, we conducted metabolomic profiling of the heart, liver and plasma and performed 16S rRNA sequencing to characterise alterations in the gut microbiome. Characteristic cardiometabolic and inflammatory profiles were observed in experimental HFpEF, including obesity, hypertension, diastolic dysfunction, hepatic steatosis, and gut dysbiosis. Despite no detectable improvement in echocardiographic function at endpoint, Dapa induced distinct hepatic remodelling, with increased citraconate, restoration of succinate, modulation of branched-chain amino acid and ketone pathways and reduced oxidative stress markers. Aromatic amino acid metabolism and gut-derived metabolites were broadly disrupted across heart, liver, and plasma. HFpEF is defined by complex, tissue-specific metabolic derangements. SGLT2 inhibition primarily remodeled the hepatic metabolome, positioning the liver as a central hub of cardio-renal-liver crosstalk. These findings suggest that extra-cardiac metabolic pathways, particularly liver-centered mechanisms, may contribute to the therapeutic benefits of SGLT2 inhibitors in HFpEF and provide new insights into inter-organ metabolic regulation.

PMID 43045850
阅读全文 →
PubMedFASEB bioAdvances2026-11-17

Dapagliflozin Mitigates Renal Fibrosis and Inflammation in Obese 5/6-Nephrectomized Rats.

Bernardo Desiree Rita Denelle DRD, Canale Daniele D, Nascimento Mariana Moura MM, Shimizu Maria Heloisa Massola MHM et al.

Obesity is a chronic disease directly and indirectly related to the progression of chronic kidney disease. Sodium-glucose cotransporter-2 inhibitors like dapagliflozin offer new renal protection strategies beyond their glucose-lowering properties. This study evaluated the effects of dapagliflozin on kidney impairment in obese rats subjected to 5/6 nephrectomy. Male Wistar rats (8 weeks old) were followed during a 100-day protocol and submitted to Nx surgery on Day 40. The animals were randomly allocated to four groups according to the diet: standard (Nx); high-fat (Nx + H); standard + dapagliflozin (Nx + D); and high-fat +dapagliflozin (Nx + H + D). Dapagliflozin (50 mg/kg diet) treatment was administered daily after Nx surgery. Assessments included anthropometrics, inulin clearance, renal hemodynamics, biochemistry, immunohistochemistry, and protein expression for inflammation and fibrosis. Dapagliflozin treatment led to reduced body weight and abdominal circumference in the Nx + H + D. It also increased glycosuria and lowered plasma glucose. Crucially, dapagliflozin restored glomerular filtration rate and attenuated the renal expression of extracellular matrix proteins, inflammatory markers, and phenotypic alterations. This resulted in a lower kidney injury score compared to the Nx + H. In summary, dapagliflozin attenuated metabolic and anthropometric parameters and mitigated the progression of kidney disease in obese rats following a 5/6 nephrectomy insult.

PMID 43041701
阅读全文 →
PubMedBiochemical and biophysical research communications2026-11-17

Biochemical reassessment of the activation of PANK1 by SGLT2 inhibitors.

Guo Zihao Z, Zang Jiahe J, Chen Lei L

Although SGLT2 inhibitors (SGLT2i) show cardiovascular benefits in addition to glycemic control, their molecular target for cardiovascular effect remains unclear. A recent study reported that two SGLT2i, empagliflozin and dapagliflozin, directly activate pantothenate kinase 1 (PANK1), which mediate their cardioprotective effect. PANK1 phosphorylates pantothenate with ATP to yield 4'-phosphopantothenate and ADP, representing the rate-limiting enzyme of coenzyme A (CoA) biosynthesis. We therefore reassessed this claim using purified recombinant human PANK1. The malachite green assay detected free inorganic phosphate (Pi) but neither ADP nor 4'-phosphopantothenate and its signals do not reflect PANK1 activity. In the ADP-Glo assay, empagliflozin and dapagliflozin did not stimulate PANK1 under either basal conditions or acetyl-CoA feedback inhibition, while the activator PZ-2891 enhanced the activity of PANK1. These results show that SGLT2i do not directly activate PANK1, challenging the proposed PANK1-dependent cardioprotection mechanism.

PMID 43044327
阅读全文 →

注册免费账户还可查看另外 4449 篇文献

免费注册查看全部文献 →

了解更多gemigliptin + dapagliflozin